Share
388 Posts.
lightbulb Created with Sketch. 75
clock Created with Sketch. 22/02/21
15:26
Share
Originally posted by Silverchair:
↑
Yes the CUV market is so well manipulated it scares many new buyers away without a doubt and I guess that the extremely low volumes also mean existing holders consider the stock well undervalued so they will not sell until a fair price is reached so liquidity is likely to remain low until higher prices are created with CUV. It's just a waiting game until stronger valuations are reached, this year or next year who knows, but I am also sure things like better comms, market forecasts, buybacks and management buying would speed this process up enormously.Clinuvel will put out a result of at least 500% increase in Year on Year half yearly profits which should grab a few headlines, can't think of many companies doing that. And that is just with US EPP sales in their very infancy and more growth to come on top of that from Israel, Australian and new Euro markets opening up - maybe even China with circa 5000+ EPP sufferers. Of course zero valuation will be given to the galactic new indications CUV is a strong chance of achieving with their very safe and FDA approved drug - and it is this 'blue sky' valuation which gives many biotechs their lofty valuations even though they have never made a single dollar of profit!!!enforcing the law rather than the “fantasy” of setting the rules. We can only hope as it seems the Corporation law is breached each day here in my view.
Expand
I'm in rough agreement with those figures, using 30% margin on the half year rev of $17.281M = $5.18M. However, cost of sales due to COVID may have increased a little, but there should be no cash used in financing activities this period, so circa $5m NPAT for the HY to 31 Dec 2020 seems fair.
(20min delay)